Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Successful expanded access use of rezafungin, a novel echinocandin, to eradicate refractory invasive candidiasis in a liver transplant recipient

(2022) Joseph Pechacek et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rezafungin: a novel antifungal for the treatment of invasive candidiasis

(2021) Young Yoon Ham et al.   Future Microbiology

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections

(2021) Christopher M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin

(2021) Jade Huguet et al.   Open Forum Infectious Diseases

Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial

(2020) George R Thompson et al.   CLINICAL INFECTIOUS DISEASES

Invasive Candidiasis Species Distribution and Trends, United States, 2009–2017

(2020) Emily E Ricotta et al.   JOURNAL OF INFECTIOUS DISEASES

We can do better: a fresh look at echinocandin dosing

(2018) Justin C Bader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Invasive candidiasis

(2018) Peter G. Pappas et al.   Nature Reviews Disease Primers

Estimation of direct healthcare costs of fungal diseases in the United States

(2018) Kaitlin Benedict et al.   CLINICAL INFECTIOUS DISEASES

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults

(2016) Taylor Sandison et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

CD101: a novel long-acting echinocandin

(2016) Yanan Zhao et al.   CELLULAR MICROBIOLOGY

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

(2015) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance

(2014) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tissue Penetration of Antifungal Agents

(2014) T. Felton et al.   CLINICAL MICROBIOLOGY REVIEWS

Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control

(2012) M. Kollef et al.   CLINICAL INFECTIOUS DISEASES

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

(2012) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts

(2011) Susan J. Howard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY